{"name":"Lytix Biopharma AS","slug":"lytix-biopharma-as","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"LTX-109 1 %","genericName":"LTX-109 1 %","slug":"ltx-109-1","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"LTX-109 1 %","genericName":"LTX-109 1 %","slug":"ltx-109-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNcHRvYmp5cFNxellIY3RIQTVwWTFLM0VqSGg5Rk9tTjRmekE4QmlIUkU4dzg0M1UwUTg4NmF0Rm1NU1hxZHFDVTNYb2k0UmFlVXpWMlhtcGdQMVJaUzZuSFBVekUxc0hrdUhfSEZCQWNUY3Z2RWNmZi1pRFNoWG9ZVGJmbnYtN3JIMnZWUURMNlZZRHpKNU01RG9qV3dsZVNXM2c?oc=5","date":"2026-04-07","type":"pipeline","source":"The Pharma Letter","summary":"Lytix Biopharma appoints Renée Christine Amundsen as COO - The Pharma Letter","headline":"Lytix Biopharma appoints Renée Christine Amundsen as COO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPTWZidjRqNllrUGFQUU1USTdMVEpETW0zT2l6YkxuZHRNZE50dms3OC1lVmxLeUhPZEtPQlItMjFnTE1QenhkQ1hfeFFFRnp1WDJVS1ZIdk1RWTJSX2FRTTF6SDdZMFdCZXhsLUhoWXBGRTJOZ0ZDeDRNQXNKTUl6NVZPN3dRa205R0VrWmV1dS1DTEV1a1VTNksxYjE?oc=5","date":"2026-04-07","type":"pipeline","source":"The Pharma Letter","summary":"Trade group sounds alarm over Belgian pharma decline - The Pharma Letter","headline":"Trade group sounds alarm over Belgian pharma decline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPQVJTbWR2bng4VkFucGowTEJGdm5wV0tnNHg3UHlOdUNmUDlTUlVTNGY4QnZyWFd0UW8wSUhITGo2TWo3NGV1Q0hGQTVxenhMWnFMeUhLakNlZnJYSU9uSGtTRjk5VHZkQWdwQUhfeU5LZG9nNGxYb0gzM2kxWkdkUmQyYWlrR1VxVjM5SnJyRFhFbmNsT0g4Nnh3?oc=5","date":"2026-03-24","type":"pipeline","source":"The Pharma Letter","summary":"The war in Iran: risks to global pharma and biotech | Pharmaceutical | The Pharmaletter - The Pharma Letter","headline":"The war in Iran: risks to global pharma and biotech | Pharmaceutical | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOVDROYTk0LWtNdlpubmVGd3J1VzZ3NjIwRmthX1hGRVRRaWV4UWZsb2pGbHA4dWo2YzdwLXo2ZGpBc3FvX2JVamQ0NFN0cHpETWlsZHozZXY0b0pWY0xodGU1Y0JrVjFGeHNWeGNiTVNYOVJLdUxlbnpRUnYtV3dDRFZVN1RJZDVXZHNjVU9mSTNLMjhvWC1JeFpjNkxiZVk?oc=5","date":"2026-02-16","type":"pipeline","source":"The Pharma Letter","summary":"Gilead strikes $1.5 billion cancer pact with Genhouse Bio - The Pharma Letter","headline":"Gilead strikes $1.5 billion cancer pact with Genhouse Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOSUlEdDByNGliMFZteEozU3Y0TC1JZUJ4MmltOGZqeENFTzI3QWNNNURMRzgxWlUzUk9saXpwbUdBZERUNGtibGtIVTlIWnl6T2xRb0trdFk1aEFJemZVWVlZYi1FYXRHRXRSNElMVFY0TlRyMXlDYXdweUw0VWwwQXl3MUNZa1RRMlhOdXh6dTRwa2VqbFpEZlliRElHalctSjd0YTlwR1lKcWU5MlROTkpnODFCZXBFbHZLX2x4cmZiU3pK?oc=5","date":"2026-02-12","type":"pipeline","source":"The Pharma Letter","summary":"Chugai’s Nicolas Henriot on agility, digital change and charting Europe’s next century - The Pharma Letter","headline":"Chugai’s Nicolas Henriot on agility, digital change and charting Europe’s next century","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNVmQxQXVRdzZzRHJ5ZkNPY2pvU2NDdUE2NUptNEgyeWlGTzFTcFdVZjRmbkZyNzZuSWd1RXpDR2g0anlreENubXozcGJWaERBWTF3UTAwZnZCNmt1emw3N1dkR2JhY3YzVXR2RU56eGpJTVo2QlIzaVFoN21tM1d5Z3BrMFVMN21KdF9YYUI1aE02ZmVhLW1xTENjVQ?oc=5","date":"2026-01-06","type":"pipeline","source":"The Pharma Letter","summary":"Clarivate flags 11 therapies as 2026 drugs to watch - The Pharma Letter","headline":"Clarivate flags 11 therapies as 2026 drugs to watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPMGNJNUtSVS01dF9BYmVSbUlMdFVHQllFeVlWZDhkSnB4cE9fMnUtNm5SWVNxSV96bE9kWGQtRnotTGg4cXVwZ0doeHNlVFFhV05zaTZFNVVZWjNtTm5GWEdkWFA0eEc3X2tjbWd5amw2ZEVnWGlXYzhRTFNSRjBpRk5vUWxldWZ4RTBMOTUtRjdrSEh5SjBxTEp1S2xEbnMxcGVmZ1BCenRNdFd5eWpjYThwTWVZbVJFS0Z0dA?oc=5","date":"2025-12-24","type":"pipeline","source":"The Pharma Letter","summary":"China’s biopharma ascent signals shift in global drug development leadership - The Pharma Letter","headline":"China’s biopharma ascent signals shift in global drug development leadership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNdW90dnNVMWZwOTRDYlZGUzN6UEUyRG9DS01DOFdqUkc0S3B5QmhqcHV3aGpQZ1I0YWR6Y2dtMmJ2blVvcGI0LWxZRm1lbTl0dU5HUXhwQ2NRZFZHZUF0SHZZeU84TXlTSUdfV2p2ZWdJTlpZWkcwZEw4NXlpZ005R3VwRDZ3Z3h4ZzRpNU9KdDdINUNpMTBpV3dQZnA?oc=5","date":"2025-12-12","type":"pipeline","source":"The Pharma Letter","summary":"AstraZeneca backs Syneron Bio in near-$100m financing - The Pharma Letter","headline":"AstraZeneca backs Syneron Bio in near-$100m financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxPTmhxaDdQVGplazVBRVYzV2tlVHVTUGVEdlN2WmtLd1dCclBJREVfbU5Sby1qRVQyZGVnMFAzRWJha3p4RGlXRjRYYWx0NHU2S2k5aV9CWjVoanRRcWV2QzZFcHFTX3hJWEI0b3VSSDBSQlQ2VU9FazdzbDBVeEZyLXUxYzVSdFk1RnFsVXM3VUE4RmJaV2FXME1XczBuaS1PRERlMzlicWF1MWp6ZEllQ3NLd0JZMHB4MXN2aGtaVm5iMk5WRXVDOTJZeVRTVElNNUpBLWd2T0NVb2Z5M1dRMmF5aXZWTkFZNTU1NVV3dVdKRUpOS3FSMG1pS3B4UkZRR0FERUJQbndLeno3WTlJTmtEWC1mNVdsXzNCQ25aUzFlUU5lU01jV2F3VVVNYjVMcnh3VDJpUzRrclQ5?oc=5","date":"2025-12-04","type":"regulatory","source":"prnewswire.com","summary":"Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approvals and Expanding Patient Pool | DelveInsight - prnewswire.com","headline":"Basal Cell Carcinoma Market Poised for Steady Growth Throughout Forecast Period (2025-2034) Driven by Novel Drug Approva","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNemktTmlwM21MYjZVd2Jza1JUSzg3SXVjOERFZFU1bzFrQzBEWlpOZU9OOW1aeWdFc016NlNCTnp5MXRKSFp2SGhfZ1FNUk9yZVpNTi1DYUJ2bXdKZ2h5T3haelBpbURlV0FIT3dPa2NZRGJ0b052TFZkb2tnV3BPd195c09lVExzVzNod3pBdlQwWXFOc3BnSVZodElmbnd5OVJ2eA?oc=5","date":"2025-11-17","type":"pipeline","source":"The Pharma Letter","summary":"Positioning Barbados as the Caribbean’s life sciences hub - The Pharma Letter","headline":"Positioning Barbados as the Caribbean’s life sciences hub","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPOWt3anpwWURIRHl5WDZnemFiUUdUWmhwMVhVNU5ZSC16d25ya25Uc1hQSjVadWpydjdfeWFZbXdnZkR4Z25ETExlYnlnQ2hRQ0x6RW15OXZGUGttMTBoeWNJS0pfYlFrTlBiZDlCVmphdi1TWkt2a05BVnRmcG0tdktwUE9NNUdoN0M1eGU1c3NycXJwTjB5cXdOOVF5WFVsdkFsNDNR?oc=5","date":"2025-11-06","type":"pipeline","source":"The Pharma Letter","summary":"Arena BioWorks closes less than two years after $500m launch - The Pharma Letter","headline":"Arena BioWorks closes less than two years after $500m launch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxNTmtpYURaVEhPYkNqc0FkczdWaHNyQXpkVXRSaVRUT0RDTm42bDQ1N1d3eDh6ZXd6czdkVGdPak5IbGxaekROMEduQnJ2LUdzMFJpbTNyVlRuVDBQMmxHbFZFTlBOS3JvbkgwMVYxSEJnenNnU0dvaF9yUDMtTmxjcXVMeWRxX1hMZ3hTcXdVdFpGM0tUYjFmdHIxbDh4OE5iTVlBQ3Q4V2JyY0g1cWpnZmdzV21yMktObTJNMmY3X2FBQ2R0aXBKbEtOOElkdS1iSnd3SGNRWHNlYzdVT3VBTkh4cklVU0dsaWF2dlhmUnZKNmRBLUplLVhpSm8tODJnNVdHVWlxQUR3U1ZIRVFxYVdPczVMSXhxOGc?oc=5","date":"2023-05-10","type":"pipeline","source":"prnewswire.com","summary":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain | DelveInsight - prnewswire.com","headline":"Soft Tissue Sarcoma Pipeline Space Brims With Novel Emerging Therapies with Over 125 Key Companies Working in the Domain","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}